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Synthesis of 4-(N)-Trisnorsqualenoyl-Gemcitabine (SQ-gem).
To a mixture of trisnorsqualenoic acid (0.50 g, 1.2 mmol) and triethylamine (0.15 g, 1.4 mmol) in anhydrous THF (5 mL) cooled at 0 °C was added dropwise ethylchloroformate (0.135 g, 1.2 mmol). The mixture was stirred at 0 °C for 15 min and a solution of gemcitabine hydrochloride (0.37 g, 1.2 mmol) and triethylamine (0.15 g, 1.4 mmol) in anhydrous DMF (5 ml) was added dropwise. The reaction mixture was stirred for 72 h at room temperature and then concentrated in vacuo. Aqueous sodium hydrogen carbonate was added and the mixture was extracted with ethyl acetate (3 x 50 ml). The combined extracts were washed with water, dried over MgSO4, and concentrated under reduced pressure. The crude product was purified by chromatography on silica gel eluting with 1 to 5% methanol in dichloromethane to give pure 4-N-trisnorsqualenoyl-gemcitabine as an amorphous white solid (0.46 g, 57%).  D = 3.1 (c = 0.95, CH2Cl2); IR (neat, cm -1 ) 3500-3150, 2950, 2921, 2856, 1709, 1656, 1635, 1557, 1490, 1435, 1384, 1319, 1275, 1197, 1130, 1071 , 66.95, H, 8.27, N, 6.51. Found: C, 66.76, H, 8.40, N, 6 .39.
Synthesis of 2-Methoxy-5-(1-(3,4,5-Trimethoxyphenyl)Vinyl)Phenol (isoCA-4).
IsoCA-4 was synthesized as indicated in Figure S1 .
Procedure for the 4, Ethylidene]-Benzenesulfonohydrazide (1, Figure S1 ). To a solution of 3',4',5'-trimethoxyacetophenone (0.37 g, 1.75 mmol) in EtOH (20 mL) was added p-toluenesulfonyl hydrazide (0.39 g, 2.1 mmol 3192, 2981, 2353, 2195, 2181, 2147, 1577, 1509, 1449, 1408, 1350, 1324, 1230, 1163, 1124, 1055, 1003 4, Vinyl]Phenol . Tosylhyrazone (1) (190 mg, 0.5 mmol), PdCl 2 (MeCN) 2 (7 mg, 0.025 mmol, 5 mol %), diphenylphosphinopropane (dppp) (20 mg, 0.05 mmol, 10 mol %), and 5 ml of dioxane were mixed under argon for 5 minutes at rt. Cs 2 CO 3 (490 mg, 1.5 mmol) was then added, the reaction mixture is stirred for 1 minute and arylhalide (2) (153 mg, 0.42 mmol) is added. The mixture was stirred at 90 °C until the reaction completed by TLC analysis (4 h). The crude reaction mixture was allowed to cool to room temperature. EtOAc was added to the mixture, which was filtered through celite. After concentration, the residue was dissolved in 14 mL of EtOH and 2 mL of DCM, p-toluene sulfonic acid (433 mg, 2.52 mmol) was added. The temperature was raised to 60 °C for 2.5 h and then the mixture was cooled to rt. Water (10 mL) was added and the aqueous phase was extracted with AcOEt (3 X 15 mL). The organic phase was dried over MgSO 4 , then concentrated. The crude residue was then purified on silica gel to give the desired phenol product. 4, 
Procedure for the Synthesis of 2-Methoxy
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Analytical Methods
Preparation and Stability Studies of Squalenoyl Nanocomposites. To evaluate the optimal conditions for the preparation of SQ-gem/isoCA-4 NAs, the influence of the drugs molar ratio (isoCA-4:SQ-gem) was tested (Tables S1). The typical procedure for the preparation of the NAs, as described in the main text, was applied. Small sizes were obtained until a molar ratio isoCA-4:SQ-gem of 1. Increasing this ratio resulted into big aggregates, probably due to the precipitation of the water non soluble isoCA-4. The optimal conditions for the preparation of SQCOOH/isoCA-4 NAs were obtained in a similar procedure (Table S2 ). Small sizes were prepared only until a molar ratio isoCA-4:SQCOOH NAs of 1:2.
The stability of the SQ-gem/isoCA-4 NAs suspension after dilution in 1, 5, 10 and 50 L was also studied. The presence of the nanoparticles was detected by quasi-elastic light scattering (QELS) with a nanosizer (Zêtasizer Nano ZS Malvern; Malvern Instruments SA, Orsay, France). In spite of the huge dilution (up to 50,000 times), the presence of nanoparticles was quite clearly detected in the diluted suspension. Additionally, it was observed that the size of the nanoparticles was not changed after any dilution (see Table S3 ). Individual vials were used for each time point. The reaction mixture was incubated at 37 °C, and aliquots (300 µL) of incubation medium were removed at predetermined time points (i.e., 0, 0.5, 1, 2, 4, 8 and 24 h).
For sample preparation at 48 h, 100 µL of SQ-gem or SQ-gem/isoCA-4 (5 µmol mL -1 )
NAs were added to 400 µL of heat-inactivated FCS supplemented with 200 µg mL -1 tetrahydrouridine (THU). 500 µL of new heat-inactivated fetal calf serum were added at 24 h and 300 µL of incubation medium were removed at 48 h.
For sample preparation at 72 h, 150 µL of SQ-gem or SQ-gem/isoCA-4 (5 µmol mL -1 )
NAs were added to 350 µL of heat-inactivated FCS supplemented with 200 µg mL -1 tetrahydrouridine (THU). 500 µL of new heat-inactivated fetal calf serum were added at 24 h and 48 h, and 300 µL of incubation medium were removed at 72 h.
All samples were centrifuged at 15,000 x g during 30 min. Then, a 100 µL aliquot of the supernatants was used for sample treatment and drug quantification in the same conditions as for plasma samples in pharmacokinetic studies (see bioanalysis section below).
Quantification of Gemcitabine, SQ-gem and isoCA-4 in Biological Samples.
Pharmacokinetic and Tumor Distribution: gemcitabine, SQ-gem and isoCA-4 were quantified in mice plasma and tumor by UPLC-MS/MS. 2'-deoxycytidine and colchicine (Sigma, France) were used as internal standards (IS).
For in vivo plasma quantitation, 1 mL of acetonitrile/methanol (vol/vol) containing IS (2'deoxycytidine 0.3 µg/mL and colchicine 0.1 µg/mL) was added to 100 µL of plasma sample. Mixture was vortex-mixed and then centrifuged at 20,000 x g for 15 min at +4 °C. For in vivo tumor measurement, tissue samples (around 1 g) were homogenized in 2 ml of water containing tetrahydrouridine (12 µg/mL), using an homogenizer Ultra-Turrax IKA T25 (Imlab, France). 500 µL of acetonitrile containing IS (2'deoxycytidine 0.6 µg/mL and colchicine 0.2 µg/mL) were added to 100 µL of homogenate sample. Cellular debris were removed by spinning at 20,000 x g for 15 min at +4 °C and transferring the supernatant to a fresh tube. Then, samples were evaporated to dryness at 40 °C with a nitrogen stream in a Turbovap LV evaporator (Biotage, UK) and resuspended in 200 μL of mobile phase (A/B; 75/25; v/v). Debris were removed by spinning at 20,000 x g for 5 min at +4 °C and supernatant was transferred to an injection vial for LC-MS/MS analysis.
Bioanalysis: For both plasma and tumor extracts, 10 µL aliquot was injected into the chromatographic system. LC-MS/MS conditions were the same for both matrices. For the three compounds (i.e., gemcitabine, SQ-gem and isoCA-4) to be quantified, linear regression with 1/X2 weighing were used for calibrations which ranged from 10 to 1,700 ng/mL and from 30 to 5,000 ng/g for plasma and tumor tissue, respectively. The extract samples maintained at + 4 °C in the autosampler were chromatographically separated using a Waters ACQUITY UPLC® System with a Acquity UPLC BEH Amide 1.7 µm, 2.1x150 mm column and a reversed phase gradient over a run time of 5.5 minutes. Initial conditions consisted of mobile phase A (0.2% formic acid in water) and mobile phase B (0.2% formic acid in methanol) with a column temperature of 50 °C and a flow rate of 0.300 mL/min. The gradient conditions ramped from 5% B to 95% B between 1.0 and 2.5 min, then maintained up to 3.5 min, ramped to 5% in 0.01 min and then maintained up to 5.5 min for re-equilibration. The MS analysis was performed on a Waters Quattro Premier™ TQ Mass Spectrometer operated in positive ion electrospray MRM mode. Briefly, main tune parameters were as follows:
capillary voltage was setup at 3 kV, source temperature was 120 °C, desolvation temperature was 350 °C, cone gas flow was 100 L/Hr and desolvation gas flow was 800 L/Hr. The analytes and the IS were specifically monitored using a pair value cone voltage (V) / collision Thus, after 72 hours of treatment with free gemcitabine, the mixture of free gemcitabine with free isoCA-4, SQ-gem NAs or SQ-gem/isoCA-4 NAs, all at IC 50 concentration (IC 50 was 6, 32, 4 and 6 nM for SQ-gem/isoCA-4 NAs, SQ-gem NAs, gemcitabine and gemcitabine+isoCA-4, respectively), LS174-T cells were washed and resuspended in 100 µL 1 x Annexin V binding buffer. Subsequently, 5 μL of FITC-conjugated Annexin V and 1 μL of propidium iodide (PI) solution (100 μg mL -1 ) were added to each cell suspension. After 15 min incubation in the dark at room temperature, stained cells were analyzed by flow cytometry (Accuri 6; Accuri, Ann Arbor, MI) using a BD Accuri CFlow Plus software. All the samples were assayed in triplicate and apoptotic fraction was calculated as follows:
%=[(apoptotic cell number)/(total cell number)]×100%. Figure S1 . A Pd-catalyzed cross-coupling reaction of N-tosylhydrazone (1) with arylhalide (2) gives rise to 1,1-diarylethylene (isoCA-4). Figure S2 . Influence of duration of storage on mean size (A) and particle size distribution (PSD) (B) of squalene-based nanocomposites (i.e., SQCOOH/isoCA-4, SQ-gem and SQgem/isoCA-4 NAs). NAs were stored at refrigerator temperature for 90 days. At different time intervals (i.e., 0, 2, 3, 4, 7, 15, 30, 60 and 90 days), the average size and PSD were determined. Samples were estimated in triplicates. Statistical analysis of the data was performed using the Student's t-test. A probability, P, of less than 0.005 (P<0.005) was considered significant in this study. As SQ-gem or SQCOOH/isoCA-4 NAs stability was less than 7 or 4 days of storage, respectively, only SQ-gem/isoCA-4 NAs were analyzed for particle size and PSD at days 15, 30, 60 and 90. These results clearly suggest that isoCA-4 contributed to stabilize the SQ-gem-based nanocomposites and prevented agglomeration during 90 days of storage (4 °C). * The cells were exposed to tested compounds for 3, 6, 24 and 72 h. After exposure to the drug the cells were washed by PBS and were then analyzed by measuring the half maximal inhibitory concentration of cell proliferation or were incubated in a new medium without any drug up to 72 h with further analysis by MTT assay. *The total quantity of gemcitabine including gemcitabine and SQ-gem.
